Citizens Jmp Issues Positive Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective upped by Citizens Jmp from $25.00 to $28.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price target would suggest a potential upside of 220.55% from the stock’s current price.

BCRX has been the subject of a number of other reports. Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target for the company. Wedbush decreased their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Finally, Royal Bank Of Canada decreased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ BCRX traded down $0.10 during trading on Thursday, hitting $8.74. 2,678,377 shares of the company traded hands, compared to its average volume of 5,071,250. The company has a 50-day moving average price of $9.05 and a 200-day moving average price of $7.81. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31. The firm has a market capitalization of $2.22 billion, a P/E ratio of 7.25 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same period last year, the company posted $0.20 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Research analysts predict that BioCryst Pharmaceuticals will post 0.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at about $77,000. Farther Finance Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at about $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals News Summary

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Strong ORLADEYO sales: Q1 ORLADEYO net revenue was $148.3M, up 11% y/y (and +21% y/y on a comparable basis excluding Europe), supporting top-line momentum for BioCryst. Q1 Financial Results
• Positive Sentiment: Licensing deal for European sale: BioCryst licensed a drug candidate for European commercialization, which can accelerate market access and monetize assets outside its core U.S. franchise. Licensing Announcement
• Positive Sentiment: Analyst support remains: Wedbush cut its price target to $21 but kept an “Outperform” rating (still implying >100% upside), and Needham trimmed its PT to $16 while maintaining a “Buy” rating — both actions signal continued analyst confidence despite the pullbacks. Wedbush Coverage Needham Coverage
• Neutral Sentiment: Revenue beat but guidance roughly in line: Q1 revenue came in above consensus (~$156.4M vs. ~$151.1M est), and the company set FY26 revenue guidance of $635–$660M (close to consensus), leaving overall topline outlook largely consistent with expectations. Revenue and Estimates
• Neutral Sentiment: Earnings call highlighted pipeline progress and new risk disclosures: Management discussed growth drivers and emerging risks on the Q1 call — useful context for investors but not immediately decisive on valuation. Earnings Call Summary
• Negative Sentiment: Large GAAP EPS swing / headline miss: The company reported a GAAP EPS loss (headlined as a large negative number in some releases), creating confusion versus other reports of a small loss — the apparent significant EPS miss and negative ROE raise concerns about one‑time items and accounting that pressured sentiment. Q1 Press Release / Slides Market Reaction & Details

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.